DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
VAFIDEMSTAT
2
Small molecule
Investigational
Unknown
Unknown
Borderline Personality Disorder
Unknown
VAFIDEMSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
LZ82JLT4UP
Molecule Type:
Small molecule
Molecular Formula:
C19H20N4O2
Molecular Weight:
336.4
AlogP:
2.88
PSA:
86.2
HBD:
2.0
HBA:
#RotB:
7.0
Source:
PHORBOL MYRISTATE ACETATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Leukemia
Unknown
PHORBOL MYRISTATE ACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
NI40JAQ945
Molecule Type:
Small molecule
Molecular Formula:
C36H56O8
Molecular Weight:
616.84
AlogP:
5.75
PSA:
130.36
HBD:
3.0
HBA:
#RotB:
15.0
Source:
ONO-2952
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Translocator protein antagonist
ONO-2952
×
Maximum Phase:
2
First Approval:
None
UNII:
ZH8CPX4YNB
Molecule Type:
Small molecule
Molecular Formula:
C22H20ClFN2O2
Molecular Weight:
398.87
AlogP:
4.95
PSA:
45.33
HBD:
1.0
HBA:
#RotB:
2.0
Source:
PF-03715455
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
MAP kinase p38 alpha inhibitor
PF-03715455
×
Maximum Phase:
2
First Approval:
None
UNII:
0TJ631J0KP
Molecule Type:
Small molecule
Molecular Formula:
C35H34ClN7O3S2
Molecular Weight:
700.29
AlogP:
7.8
PSA:
129.6
HBD:
4.0
HBA:
#RotB:
10.0
Source:
EMVODODSTAT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Neurofibromatosis 2
Unknown
EMVODODSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H20Cl2N2O3
Molecular Weight:
467.35
AlogP:
6.63
PSA:
54.56
HBD:
1.0
HBA:
#RotB:
3.0
Source:
CYTIDINE
2
Small molecule
Investigational
Unknown
Unknown
Bipolar Disorder
Unknown
CYTIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
5CSZ8459RP
Molecule Type:
Small molecule
Molecular Formula:
C9H13N3O5
Molecular Weight:
243.22
AlogP:
-2.56
PSA:
130.83
HBD:
4.0
HBA:
#RotB:
2.0
Source:
GSK2838232
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
GSK2838232
×
Maximum Phase:
2
First Approval:
None
UNII:
G9C7884M8M
Molecule Type:
Small molecule
Molecular Formula:
C48H73ClN2O6
Molecular Weight:
809.57
AlogP:
9.46
PSA:
107.38
HBD:
2.0
HBA:
#RotB:
13.0
Source:
BERUBICIN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Glioblastoma; Glioma
DNA topoisomerase II inhibitor
BERUBICIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
7BA3X03948
Molecule Type:
Small molecule
Molecular Formula:
C34H36ClNO11
Molecular Weight:
670.11
AlogP:
2.23
PSA:
195.07
HBD:
5.0
HBA:
#RotB:
8.0
Source:
HEME ARGINATE
2
Small molecule
Investigational
Unknown
Unknown
Myocardial Infarction; Acute Kidney Injury; Myocardial Ischemia; Porphyrias; Reperfusion Injury
Unknown
HEME ARGINATE
×
Maximum Phase:
2
First Approval:
None
UNII:
R1B526117P
Molecule Type:
Small molecule
Molecular Formula:
C40H48FeN8O6+2
Molecular Weight:
792.72
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
RADEZOLID
2
Small molecule
Investigational
Unknown
Unknown
Pneumonia
Bacterial 70S ribosome inhibitor
RADEZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
53PC6LO35W
Molecule Type:
Small molecule
Molecular Formula:
C22H23FN6O3
Molecular Weight:
438.46
AlogP:
2.36
PSA:
112.24
HBD:
3.0
HBA:
#RotB:
8.0
Source:
GPI-1485
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Unknown
GPI-1485
×
Maximum Phase:
2
First Approval:
None
UNII:
0709BVY57W
Molecule Type:
Small molecule
Molecular Formula:
C12H19NO4
Molecular Weight:
241.29
AlogP:
1.07
PSA:
74.68
HBD:
1.0
HBA:
#RotB:
4.0
Source:
EXEPORFINIUM CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Staphylococcal Infections
Unknown
EXEPORFINIUM CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1912L54M2V
Molecule Type:
Small molecule
Molecular Formula:
C44H50Cl2N6O2
Molecular Weight:
765.83
AlogP:
8.94
PSA:
75.82
HBD:
2.0
HBA:
#RotB:
12.0
Source:
IBOGAINE
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Opioid-Related Disorders
Unknown
IBOGAINE
×
Maximum Phase:
2
First Approval:
None
UNII:
3S814I130U
Molecule Type:
Small molecule
Molecular Formula:
C20H26N2O
Molecular Weight:
310.44
AlogP:
3.94
PSA:
28.26
HBD:
1.0
HBA:
#RotB:
2.0
Source:
BIMOSIAMOSE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis; Pulmonary Disease, Chronic Obstructive
Selectin inhibitor
BIMOSIAMOSE
×
Maximum Phase:
2
First Approval:
None
UNII:
97B5KCW80W
Molecule Type:
Small molecule
Molecular Formula:
C46H54O16
Molecular Weight:
862.92
AlogP:
1.98
PSA:
273.36
HBD:
10.0
HBA:
#RotB:
19.0
Source:
TETRAHYDROURIDINE
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Anemia, Sickle Cell; Central Nervous System Neoplasms; Head and Neck Neoplasms; Myelodysplastic Syndromes; Neoplasms; Carcinoma, Non-Small-Cell Lung
Unknown
TETRAHYDROURIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
0NIZ8H6OL8
Molecule Type:
Small molecule
Molecular Formula:
C9H16N2O6
Molecular Weight:
248.24
AlogP:
-2.84
PSA:
122.49
HBD:
5.0
HBA:
#RotB:
2.0
Source:
AZD4205
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Lymphoma, T-Cell, Peripheral
Tyrosine-protein kinase JAK1 inhibitor
AZD4205
×
Maximum Phase:
2
First Approval:
None
UNII:
3BY9Z3M34G
Molecule Type:
Small molecule
Molecular Formula:
C25H31N9O2
Molecular Weight:
489.58
AlogP:
2.69
PSA:
116.23
HBD:
3.0
HBA:
#RotB:
7.0
Source:
ODELEPRAN
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism
Opioid receptors; mu/kappa/delta antagonist
ODELEPRAN
×
Maximum Phase:
2
First Approval:
None
UNII:
4VZT670SD9
Molecule Type:
Small molecule
Molecular Formula:
C20H24FN3O3
Molecular Weight:
373.43
AlogP:
3.02
PSA:
86.47
HBD:
2.0
HBA:
#RotB:
8.0
Source:
POSELTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Tyrosine-protein kinase BTK inhibitor
POSELTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
D01E4B1U35
Molecule Type:
Small molecule
Molecular Formula:
C26H26N6O3
Molecular Weight:
470.53
AlogP:
4.64
PSA:
95.76
HBD:
2.0
HBA:
#RotB:
7.0
Source:
NARONAPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 4 (5-HT4) receptor agonist
NARONAPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
058896B00B
Molecule Type:
Small molecule
Molecular Formula:
C27H41ClN4O5
Molecular Weight:
537.1
AlogP:
2.95
PSA:
106.36
HBD:
2.0
HBA:
#RotB:
11.0
Source:
PF-04531083
2
Small molecule
Investigational
Unknown
Unknown
Chronic Pain; Toothache
Sodium channel protein type X alpha subunit blocker
PF-04531083
×
Maximum Phase:
2
First Approval:
None
UNII:
40497CY7Y3
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PSI-352938
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
PSI-352938
×
Maximum Phase:
2
First Approval:
None
UNII:
3Z30JH9QX1
Molecule Type:
Small molecule
Molecular Formula:
C16H23FN5O6P
Molecular Weight:
431.36
AlogP:
2.38
PSA:
132.84
HBD:
1.0
HBA:
#RotB:
5.0
Source:
METHOXYAMINE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Glioblastoma
Unknown
METHOXYAMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
9TZH4WY30J
Molecule Type:
Small molecule
Molecular Formula:
CH5NO
Molecular Weight:
47.06
AlogP:
-0.49
PSA:
35.25
HBD:
1.0
HBA:
#RotB:
0.0
Source:
CARMEGLIPTIN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitor
CARMEGLIPTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
9Z723VGH7J
Molecule Type:
Small molecule
Molecular Formula:
C20H28FN3O3
Molecular Weight:
377.46
AlogP:
1.52
PSA:
68.03
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ELOCALCITOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Vitamin D receptor agonist
ELOCALCITOL
×
Maximum Phase:
2
First Approval:
None
UNII:
2WDS5F2V6Q
Molecule Type:
Small molecule
Molecular Formula:
C29H44O3
Molecular Weight:
440.67
AlogP:
6.18
PSA:
60.69
HBD:
3.0
HBA:
#RotB:
7.0
Source:
FIRATEGRAST
2
Small molecule
Investigational
Unknown
Unknown
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Integrin alpha-4/beta-1 antagonist
FIRATEGRAST
×
Maximum Phase:
2
First Approval:
None
UNII:
OJY3SK9H5F
Molecule Type:
Small molecule
Molecular Formula:
C27H27F2NO6
Molecular Weight:
499.51
AlogP:
4.61
PSA:
94.09
HBD:
2.0
HBA:
#RotB:
11.0
Source:
AZD7009
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation
HERG blocker
AZD7009
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C23H34N4O5
Molecular Weight:
446.55
AlogP:
1.21
PSA:
107.29
HBD:
2.0
HBA:
#RotB:
8.0
Source:
TEDIZOLID
2
Small molecule
Investigational
Unknown
Unknown
Infections; Bacterial Infections
Bacterial 70S ribosome inhibitor
TEDIZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
97HLQ82NGL
Molecule Type:
Small molecule
Molecular Formula:
C17H15FN6O3
Molecular Weight:
370.34
AlogP:
1.4
PSA:
106.26
HBD:
1.0
HBA:
#RotB:
4.0
Source:
AFP-464 FREE SALT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AFP-464 FREE SALT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C24H27F3N4O3
Molecular Weight:
476.5
AlogP:
3.94
PSA:
137.37
HBD:
4.0
HBA:
#RotB:
9.0
Source:
X-396
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
X-396
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY-2608204
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
LY-2608204
×
Maximum Phase:
2
First Approval:
None
UNII:
5A0L003HEY
Molecule Type:
Small molecule
Molecular Formula:
C28H37N3O3S3
Molecular Weight:
559.82
AlogP:
5.74
PSA:
79.37
HBD:
1.0
HBA:
#RotB:
10.0
Source:
FADOLMIDINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FADOLMIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
WLN5FGH1CY
Molecule Type:
Small molecule
Molecular Formula:
C13H14N2O
Molecular Weight:
214.27
AlogP:
2.39
PSA:
48.91
HBD:
2.0
HBA:
#RotB:
2.0
Source:
RSV-604
2
Small molecule
Investigational
Unknown
Unknown
Respiratory Syncytial Virus Infections
Nucleoprotein inhibitor
RSV-604
×
Maximum Phase:
2
First Approval:
None
UNII:
6NF9HI6D98
Molecule Type:
Small molecule
Molecular Formula:
C22H17FN4O2
Molecular Weight:
388.4
AlogP:
3.76
PSA:
82.59
HBD:
3.0
HBA:
#RotB:
3.0
Source:
NRX195183
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Promyelocytic, Acute
Retinoic acid receptor alpha agonist
NRX195183
×
Maximum Phase:
2
First Approval:
None
UNII:
RC87L028HU
Molecule Type:
Small molecule
Molecular Formula:
C22H22ClF2NO4
Molecular Weight:
437.87
AlogP:
5.62
PSA:
86.63
HBD:
3.0
HBA:
#RotB:
3.0
Source:
TEMUTERKIB
2
Small molecule
Investigational
Unknown
Unknown
Glioblastoma; Leukemia, Myeloid, Acute; Neoplasms; Pancreatic Neoplasms
Mitogen-activated protein kinase; ERK1/ERK2 inhibitor
TEMUTERKIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H27N7O2S
Molecular Weight:
453.57
AlogP:
2.71
PSA:
88.41
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ELZASONAN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 1b (5-HT1b) receptor antagonist
ELZASONAN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
X38F62RR8L
Molecule Type:
Small molecule
Molecular Formula:
C22H24Cl3N3OS
Molecular Weight:
484.88
AlogP:
4.87
PSA:
26.79
HBD:
0.0
HBA:
#RotB:
3.0
Source:
1
2
…
111
112
113
114
115
116
117
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA